Regeneron And Bayer Report Positive Results For VEGF Trap-Eye In Phase 3 Study In Central Retinal Vein Occlusion (CRVO) And In Phase 2 Study In Diabetic Macular Edema (DME)

Regeneron Pharmaceuticals, Inc. and Bayer HealthCare today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the COPERNICUS study, which is led by Regeneron, the first of two Phase 3 studies in patients with macular edema due to central retinal vein occlusion (CRVO). In this trial, 56.1 percent of patients receiving VEGF Trap-Eye 2 milligrams (mg) monthly gained at least 15 letters of vision from baseline, compared to 12.3 percent of patients receiving sham injections (p<0.0001), the primary endpoint of the study. Patients receiving VEGF Trap-Eye 2mg monthly (Read more...)

Full Story →